The impact of the national reimbursement drug list negotiation policy on the accessibility and utilization of evolocumab and alirocumab in different levels of hospitals: an interrupted time series analysis.

ABSTRACT:

Objective

In December 2021, evolocumab and alirocumab were included in the National Reimbursement Drug List Negotiation (NRDLN), with implementation commencing in January 2022. This study aimed to evaluate the impact of the NRDLN policy on the clinical utilization of two novel lipid-lowering agents in different levels of hospitals.

Methods

Data on evolocumab and alirocumab were collected from 910 tertiary and secondary public general hospitals across 31 provinces or autonomous regions in China (from January 2020 to December 2023) via the China Pharmaceutical Information Network (CPIN). Interrupted Time Series (ITS) analysis was employed to evaluate changes in drug availability, Defined Daily Doses (DDDs), and Defined Daily Dose cost (DDDc) before and after the inclusion of t

SUBMITTER: Tang W 

PROVIDER: S-EPMC12497621 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature